Testing a new medication for advanced lung cancer with a specific genetic mutation

This study is testing sotorasib, a targeted medication designed to work against a specific genetic change (KRAS p.G12C) found in some lung cancers. The trial will give you the medication in two phases: an initial treatment phase lasting about 2 months, followed by a longer treatment phase if your cancer responds well. Researchers want to see whether this medication can slow or stop the growth of stage III lung cancer that cannot be removed by surgery and for which standard chemotherapy combined with radiation is not a safe option.

Many patients with advanced lung cancer cannot have surgery or standard chemotherapy combined with radiation because of the size or location of their tumor or because they have other health conditions that make these treatments too risky. This medication offers a new treatment option that targets the specific genetic mutation driving some of these cancers, potentially providing benefit with fewer side effects than traditional approaches.